Certificate under Regulation 74(5) of the SEBI (Depositories and Participants Regulations, 2018 for the quarter ended June 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Venmax Drugs and Pharmaceuticals has submitted a routine quarterly compliance certificate to BSE for the quarter ended June 30, 2025. The certificate was issued by CIL Securities Limited, the company's Registrar and Share Transfer Agent (RTA). It confirms that all share certificates received from Depository Participants for demat conversion during the quarter were properly verified, listed on the stock exchange, mutilated, and cancelled, with the demat account holders' names substituted in the company's register of members within the required timeline. The filing was signed by Whole Time Director Venkata Rao Sadhanala. There are no financial figures, transactions, or corporate actions disclosed in this filing.
This is a routine regulatory compliance filing with no material impact on the company's financials, operations, or stock price. Shareholders should not read any signal into it — it is a standard procedural requirement that every listed company with a physical-to-demat share conversion process must fulfil each quarter.